{"id":804,"date":"2025-03-21T06:00:23","date_gmt":"2025-03-21T06:00:23","guid":{"rendered":"https:\/\/perfusfind.com\/ic\/?p=804"},"modified":"2025-03-20T23:50:31","modified_gmt":"2025-03-20T23:50:31","slug":"haloperidol-in-treating-delirium-reducing-mortality-and-preventing-delirium-occurrence-bayesian-and-frequentist-meta-analyses","status":"publish","type":"post","link":"https:\/\/perfusfind.com\/ic\/index.php\/2025\/03\/21\/haloperidol-in-treating-delirium-reducing-mortality-and-preventing-delirium-occurrence-bayesian-and-frequentist-meta-analyses\/","title":{"rendered":"Haloperidol in treating delirium, reducing mortality, and preventing delirium occurrence: Bayesian and frequentist meta-analyses"},"content":{"rendered":"

Summary of Haloperidol in Treating Delirium, Reducing Mortality, and Preventing Delirium Occurrence: Bayesian and Frequentist Meta-Analyses<\/p>\n

\n
\n
<\/div>\n<\/div>\n

Abstract<\/h3>\n

This study evaluates the efficacy and safety of haloperidol<\/strong> for delirium treatment and prevention<\/strong> in ICU patients using Bayesian and frequentist meta-analyses<\/strong>. Seven RCTs (n = 1,767)<\/strong> assessed delirium treatment, while five RCTs (n = 2,509)<\/strong> examined delirium prevention. The Bayesian analysis showed that haloperidol had a 68% probability of reducing all-cause mortality<\/strong> and a 78% probability of reducing benzodiazepine use<\/strong> in delirium treatment. However, for delirium prevention<\/strong>, haloperidol had low probabilities of clinical benefit<\/strong> and a 65% probability of prolonging QTc intervals<\/strong>, raising safety concerns. The results suggest that haloperidol is beneficial for treating delirium but not for prevention<\/strong>.<\/p>\n

\n
\n
<\/div>\n<\/div>\n

Key Points<\/h3>\n
    \n
  1. \n

    Haloperidol is commonly used in ICU patients with delirium<\/strong>, but evidence for its efficacy remains inconclusive. This meta-analysis evaluates its role in delirium treatment and prevention<\/strong>.<\/p>\n<\/li>\n

  2. \n

    Bayesian analysis showed a 68% probability of reducing all-cause mortality<\/strong> in delirium treatment, while the frequentist analysis did not find a significant reduction in mortality risk.<\/p>\n<\/li>\n

  3. \n

    For delirium treatment, haloperidol had a 78% probability of reducing the need for rescue benzodiazepine use<\/strong>, which may contribute to better patient outcomes.<\/p>\n<\/li>\n

  4. \n

    The risk of serious adverse events (SAEs) was low<\/strong>, with only a 2% probability of significant harm in delirium treatment.<\/p>\n<\/li>\n

  5. \n

    Haloperidol did not significantly prevent the onset of delirium<\/strong>, with only a 34% probability of reducing delirium incidence<\/strong>.<\/p>\n<\/li>\n

  6. \n

    A key safety concern in delirium prevention was QTc prolongation<\/strong>, where haloperidol had a 65% probability of causing clinically important QTc prolongation<\/strong>, increasing the risk of arrhythmias.<\/p>\n<\/li>\n

  7. \n

    Frequentist meta-analysis found no significant differences in ICU or hospital length of stay<\/strong> between haloperidol and placebo for both delirium treatment and prevention.<\/p>\n<\/li>\n

  8. \n

    The use of haloperidol for prophylactic delirium prevention is not recommended<\/strong> due to the low likelihood of benefit and potential cardiac risks.<\/p>\n<\/li>\n

  9. \n

    Limitations include variations in haloperidol dose, route of administration, and the heterogeneity of ICU patients<\/strong>, making the results less generalizable.<\/p>\n<\/li>\n

  10. \n

    Future research should focus on predictive factors for haloperidol\u2019s benefits and risks<\/strong> in specific ICU patient populations, such as post-surgical or high-risk patients.<\/p>\n<\/li>\n<\/ol>\n

    \n
    \n
    \n
    \n
    Minimize image<\/div>\n
    Edit image<\/div>\n
    Delete image<\/div>\n<\/div>\n<\/div>\n

    \"\"<\/div>

    Posterior probability of haloperidol versus placebo for delirium treatment on the primary outcomes. The distribution chart on the right, yellow represents the probability of exceeding the clinical important benefit, while pink represents the probability of being below the clinical important benefit. For the values on the left, yellow represents the benefit values, and pink represents the harm values. Abbreviation: CIB\u2009=\u2009clnically imporant benefit; CIH\u2009=\u2009clinically imporant harm. aDotted line indicates clinical important benefit, and solid line indicates no difference. bThe cut-off point for clinically important benefit is \u22120.02 for risk difference and 0.9 for risk ratio, while the cut-off point for clinically important harm is 0.02 for risk difference and 1.1 for risk ratio<\/figcaption><\/figure>\n
    \n
    \n
    <\/div>\n<\/div>\n

    Conclusion<\/h3>\n

    Haloperidol may be effective for treating delirium<\/strong> in ICU patients, with potential benefits in reducing mortality and benzodiazepine use<\/strong>, but it is not recommended for delirium prevention<\/strong> due to lack of efficacy and increased QTc prolongation risks<\/strong>. These findings provide clinicians with a more nuanced understanding<\/strong> of haloperidol\u2019s role in critical care settings.<\/p>\n

    \n

    ACCESS FULL ARTICLE HERE<\/a><\/p>\n<\/blockquote>\n

    \n
    \n
    \n
    \n
    Minimize image<\/div>\n
    Edit image<\/div>\n
    Delete image<\/div>\n<\/div>\n<\/div>\n

    \"\"<\/div>

    Haloperidol in treating delirium, reducing mortality, and preventing delirium occurrence: Bayesian and frequentist meta-analyses<\/figcaption><\/figure>\n
    \n

    Watch the following video on “Haloperidol for the Treatment of Delirium in ICU Patients” by Psychopharmacology Institute<\/strong><\/p>\n